Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Dr. Brian Callaghan discusses the AAN's comments at a recent ICER meeting on the cost-effectiveness of aducanumab, the newly approved drug for Alzheimer's disease.